Photo of Manni Mohyuddin from patientpower.info
Nov 6, 2023, 17:36
Manni Mohyuddin: Every day in my clinic, there is selection bias in favor of an increase in PFS for CAR T-cell therapy
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared on X/Twitter:
“Every day in my clinic, there is selection bias in favor of an increase in Progression-free survival (PFS) for CAR T-cell therapy.
- Aggressive disease, rapidly rising light chains: Give Bispecific T-cell engager (BiTE).
- Indolent progressions, planning for next treatment in advance: Think CAR T-cell therapy.
Cilta-cel real-world Progression-free survival (PFS) will be stellar for this reason, in my opinion.
We have many debates on CART versus Bispecific T-cell engager (BiTE). But for those who desperately imminently need therapy now for progressions- BiTE beat CART out of the park.”
Source: Manni Mohyuddin/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12